Immuno-oncology Insights’ Post

🧑💻Join me and members of my Tempus Translational team this Wednesday where I will be moderating a virtual panel. 🧬 We'll be providing a live demo of LENS, our AI-enabled cloud platform that sits on top of our real-world database AND 💊 presenting user stories of how our scientists are leveraging LENS with our biopharma partners across multiple phases of drug development. ✉️ Feel free to reach out to me if you have any questions before or after the webinar. 👇 Register Below #biotech #biopharma #biomarkers #compbio #rwe #realworlddata #clinicaltrials #oncology #drugdiscovery #preclinical

Unlocking the Power of Precious Samples with BD Cell and Biomarker Preservation Tubes! Ambitious research begins with valuable samples. Research relies on consistency and reliable methods to gain valuable insights. But did you know that pre-analytical variables account for 62% of errors in the clinical environment? That’s where BD Vacutainer® steps in! With over 70 years of blood specimen management experience, we’re here to revolutionize your research. Learn More about BD's Cell and Biomarker Preservation Solutions: https://buff.ly/3zCI6Os BD—the trusted name in blood specimen management! BD-Canada

Why would designer antibodies matter? Recombinant or designer antibodies have mutated Fc regions to clean up your flow assays from unspecified binding. Join our R&D team in this webinar and ask away! #flowcytometry #antibodies

Missed our recent webinar? You can still watch it and learn how mass photometry can streamline your antibody characterization workflows. Through a series of case studies, you can discover how this column-free technology can quickly measure mAb sample quality, accommodating diverse buffers and requiring minimal sample amount. Additionally, you can learn how it compares with the gold-standard SEC for measuring antibody aggregation and explore its potential for broader applications, such as the study of complex antibody-antigen interactions.  🔬 Watch now 👉 https://lnkd.in/d4-fWJrg In partnership with The Scientist

Are you tackling ‘undruggable’ targets in your research? Join Promega’s virtual symposium, Cracking the Undruggable Code, and discover the latest strategies your peers are using to overcome these challenges. Don’t miss out—register today! #TargetedProteinDegradation #Proteomics #DrugDiscovery #UndruggableTargets #PROTACs #MolecularGlues #DrugDevelopment #Biopharma #ProteinResearch #Biotechnology #Pharmaceuticals

Win a free pilot study using Olink Proteomics’s Target 48 cytokine panel, along with a statistical data analysis prepared by our collaborative partner Biogenity. This panel has been specifically developed for inflammation studies, containing 45 carefully selected protein assays for key pathways associated with cytokine signaling and other inflammatory processes. With just 1 µL of sample, this panel can provide insights into: ·        Treatment safety and efficacy ·        Patient immune responses ·        Disease phenotype ·        Inflammatory diseases ·        Molecular mechanisms underlying disease. To be in the running to win this opportunity please visit our website www.diagnostik.dtu.dk and submit your abstract by the 05.04.24. The following terms and conditions apply to this competition:   ·        Maximum of 40 samples either serum or plasma. ·        Abstract limit of 250 words.  ·        The samples must be ready to shipping by the end of May 2024. ·        The winner will be announced 26.04.24. #drugdiscovery #proteomics  #medicalsciences #biomarkers #development #healthcare #clinicalstudies #pharma #medical  #biopharma #pharmacovigilance #medicalaffairs #pharmaindustry #oncology #drugdevelopment #cra #biotechnology #cro #translationalresearch #precisionmedicine #inflammatory #diseases #cytokines #panels #competition #win #pilot #study #cfd

In our interview, Worldwide Clinical Trials’ expert Jayaprakash Kotha discusses the two main immunogenicity assessments for large molecule bioanalysis, ADA and Nab testing, and how multiplex analysis is now commonplace. Find out more here >>> https://hubs.ly/Q02H3m6Q0

Gain valuable insights into the industry's latest trends, innovations, and future prospects in this recent Life Sciences Knowledge Hub interview, featuring BIOVECTRA's Marc Sauer and Jessica Madigan. Dive into the conversation here: https://lnkd.in/gGHkhKMm

Learn how to reliably culture, differentiate, and expand T-cells using chemically defined media and recombinant human proteins from FUJIFILM Irvine Scientific. Attend our presentation on February 28th, at 2:30 PM GMT with Field Application Scientist, Ivo Urh, and stop by booth 13 to discover the benefits of chemically defined conditions in your cell culture process. https://brnw.ch/21wHdD8

#AI incorporation into clinic, imagine in overburdened healthcare environments how we can aid in #diagnostics and unlock new #treatments. Join our fun discussion tomorrow -register https://hubs.la/Q02sf-HL0